Register Now for Live Event Nov. 18: Improving Survival in Early Stage NSCLC by Incorporating a 14 Gene Molecular Risk Diagnostic Assay

Register Now!

CTSNet presents

Improving Survival in Early Stage NSCLC by Incorporating a 14 Gene Molecular Risk Diagnostic Assay

CTSNet is pleased to host a live event at 10 am CT (US) on November 18 that will shed light on important recent developments in lung cancer treatment.

Moderated by David Jablons, MD, University of California San Francisco, who will be joined by an esteemed panel, this live event will present data about the development of a molecular assay based on resected tumor RNA expression from simple paraffin-fixed tissue samples. This is integrated into an algorithm that can assign a risk score for recurrence. This molecular risk score is fully independent of standard TNM staging and does not rely on any other clinical parameters. The assay has been widely validated in thousands of patients and demonstrates both significant prognostic information and the predictive benefit of adjuvant platinum based chemotherapy in high risk patients as identified by this assay.

The panel will present several interesting and illustrative real life cases of the clinical utility of the assay and discuss relevance and utilization.

Join the discussion on Wednesday, November 18, at 10:00 am Central (US)

Click here for a time zone conversion website

Register now for this FREE Live Webinar

Moderator:

David M. Jablons, MD
Chief of Thoracic Surgery
University of California San Francisco

Panelists:

Gavitt A. Woodard, MD
Assistant Professor of Surgery, Division of Thoracic Surgery
Yale School of Medicine

Melissa H. Coleman, MD
Clinical Instructor, Thoracic Surgeon
University of California San Francisco

Collin Blakely, MD
Assistant Professor of Medicine, Thoracic Medical Oncologist
University of California San Francisco

Register now for this FREE Live Webinar

Use #CTSNetLive when you share on social media!